Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.33 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PDXK | O00764 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4483339 | 0.82 | ALDH1A1 (0.38) | AGXTCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL3393038 | 0.80 | HSP90AA1 (0.40) | AGXTCCR1CCR5CCR8HSP90AA1 | |
| SCHEMBL3180063 | 0.80 | HSP90AA1 (0.41) | AGXTCCR1CCR5CCR8HSP90AA1 | |
| SCHEMBL3394671 | 0.80 | HSP90AA1 (0.40) | AGXTCCR1CCR5CCR8HSP90AA1 | |
| SCHEMBL27885003 | 0.80 | HSP90AA1 (0.41) | AGXTCCR1CCR5CCR8HSP90AA1 | |
| SCHEMBL10440855 | 0.79 | AGXT (0.51) | AGXTCCR1CCR5CCR8HSP90AA1 | |
| SCHEMBL29382857 | 0.79 | AGXT (0.66) | AGXTHSP90AA1HSP90AB1ALDH1A1KDM4E | |
| SCHEMBL3802238 | 0.79 | AGXT (0.36) | AGXTALDH1A1KDM4EHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL7672150 | 0.79 | HSP90AA1 (0.40) | AGXTHSP90AA1HSP90AB1ALDH1A1KDM4E | |
| SCHEMBL1060082 | 0.79 | AGXT (0.66) | AGXTHSP90AA1HSP90AB1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531639-A | Layered aluminophosphates as catalysts for beckmann rearrangement | 艾德凡斯化学公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-107406394-A | For the method for the phenyl-isoxazole oxazoline derivative for preparing substitution | 拜耳作物科学股份公司 | 2017-11-28 | — | — | CN | disclosed |
| US-8852554-B2 | Radiolabelled PDE10 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2493513-B1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-30 | — | — | EP | disclosed |
| EP-2493513-A1 | RADIOLABELLED PDE10 LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051324-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 1906/4885CCR1 4568/4885CCR5 4618/4885 |
| US-20120213703-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | AGXT 3699/4885CCR1 1110/4885CCR5 366/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 1906/4885CCR1 4568/4885CCR5 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.